###begin article-title 0
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia
###end article-title 0
###begin p 1
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 801 802 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 859 863 859 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 1067 1074 1067 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1290 1297 1290 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1354 1358 1354 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 1430 1434 1430 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 1510 1514 1510 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 691 699 <span type="species:ncbi:9606">patients</span>
###xml 830 838 <span type="species:ncbi:9606">patients</span>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 886 894 <span type="species:ncbi:9606">patients</span>
###xml 940 948 <span type="species:ncbi:9606">patients</span>
###xml 983 990 <span type="species:ncbi:9606">patient</span>
###xml 1001 1009 <span type="species:ncbi:9606">patients</span>
###xml 1122 1130 <span type="species:ncbi:9606">patients</span>
###xml 1189 1197 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
###xml 1276 1283 <span type="species:ncbi:9606">patient</span>
###xml 1492 1500 <span type="species:ncbi:9606">patients</span>
FLT3 mutations are common genetic changes, and are reported to have prognostic significance in acute myeloid leukemia (AML). The FLT3 internal tandem duplication (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD) were analyzed by polymerase chain reaction (PCR) in the genomic DNA of Korean patients with AML at diagnosis and during follow-up. There were 226 patients with AML enrolled between March 1996 and August 2005. The incidence of ITD and TKD at diagnosis was 13% (29/226) and 3% (6/226). When compared to Western and other Asian patients with AML, Korean patients had a lower frequency by about two-thirds of ITD and TKD. Among the non-M3 cases (N=203), the patients with an ITD had a significantly shorter event-free survival when compared with those without an ITD (p=0.0079). Among 54 relapsed patients, 9 patients had the FLT3 ITD at diagnosis. Six patients demonstrated a reappearance of the ITD and 3 patients remained negative at relapse. One patient, among 45 patients who relapsed, had a negative baseline ITD but acquired a de novo ITD at relapse. There were 101 samples from 93 patients in remission; they were all negative for an ITD. Among 34 patients who failed to achieve a remission, five patients had a persistent ITD and one patient had a de novo ITD. These results support the concept of resistance of FLT3 ITD leukemic clones to chemotherapy. Therefore, effective therapy with FLT3 targeting agents may improve the prognosis of non-M3 AML patients with the FLT3 mutation.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 776 780 776 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 914 915 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 483 491 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
###xml 993 1001 <span type="species:ncbi:9606">patients</span>
FLT3 mutations are common cytogenetic changes in acute myeloid leukemia (AML). Internal tandem duplication (ITD) of exon 14 or 15 is detected in 20-30% of patients (1-3) and a mutation of D835 in exon 20 in 7% of patients (4-7). Many clinical studies have shown that patients with an ITD at diagnosis have frequent disease relapse and a short duration of survival when compared to patients without an ITD (8-17). Two prior Korean trials included 165 adult (14) and 61 pediatric (16) patients with AML, and showed similar results; patients with an ITD at diagnosis had reduced event-free survival and similar overall survival when compared to patients without an ITD. The incidence of ITD in the 2 Korean studies was 35.2% and 6.6%, respectively (14, 16). A second mutation of FLT3 involves the tyrosine kinase domain (TKD) at D835. Its incidence is relatively low and its prognostic value has not been determined (8, 14, 18). However, one of several studies on TKD showed that the survival of patients with TKD at diagnosis was longer than those without TKD (18).
###end p 3
###begin p 4
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 482 486 482 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
Several studies have investigated the variability of the FLT3 mutation in patients with AML during treatment (13, 17, 19-22). When compared to diagnosis, leukemic relapse occurred with persistent, newly developed or disappeared ITD. Because of the small number of patients in prior studies, the understanding of the FLT3 changes is incomplete. In addition, the role of the FLT3 status in disease remission or persistence during therapy has not been evaluated. Therefore, we studied FLT3 mutations (ITD and TKD) at diagnosis and evaluated their variability during disease remission relapse or persistence with therapy in Korean patients with AML.
###end p 4
###begin title 5
MATERIALS AND METHODS
###end title 5
###begin title 6
Eligibility
###end title 6
###begin p 7
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 738 745 <span type="species:ncbi:9606">patient</span>
###xml 836 844 <span type="species:ncbi:9606">patients</span>
From March 1996 to August 2005, 226 patients from three centers were diagnosed with AML and underwent induction chemotherapy according to the center's protocol usually including anthracycline and cytarabine. Among them, 33 patients did not receive chemotherapy. Twenty-four patients did not receive chemotherapy due to co-morbid conditions or advanced age, and pretreatment mortality occurred in nine patients. All patients' bone marrow (BM) samples at diagnosis were available, but samples after induction were available for 111 patients. BM samples were classified into four groups: Group A samples at diagnosis, Group B first relapse or more, Group C first remission or more, and Group D first induction failure or more. The number of patient samples available at diagnosis and relapse was 54 for A/B, 91 for A/C and 28 for A/D. All patients provided informed consent and the individual institutional review boards at each center approved the study protocol.
###end p 7
###begin title 8
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
Detection of FLT3 ITD and TKD
###end title 8
###begin p 9
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 682 683 674 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 714 718 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 879 882 871 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 316 323 <span type="species:ncbi:9606">patient</span>
Mononuclear cells from the BM aspirate were isolated using Histopaque-1077 (Sigma, St. Louis, MO, U.S.A.) and then DNA was extracted using the QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) for the ITD was carried out as described previously (1). We used a 100 ng sample of each patient's DNA, which was amplified in a 36-cycle PCR reaction at an annealing temperature of 56â„ƒ. We used 10 microM/L of two reverse primers (11R of 5'-ACTCTA AATTTTCTCT-3', and 12R of 5'-CTTTCAGCATTTTGACGGCAACC-3') for each reaction and 10 microM/ L of a common forward primer (3'-GCAATTTAGGTATGAAAGCCAGC-5'). The PCR for TKD was performed as described previously (3). We amplified exon 17 of the FLT3 gene by the genomic PCR method using the primers (17F of 5'-CCGCCAGGAACGTGCTTG-3', and 17R of 5'-GCAG-CCTCACATTGCCCC-3'). Amplified products were digested with Eco RV; then they were subjected to electrophoresis on an agarose gel.
###end p 9
###begin title 10
Statistical analysis
###end title 10
###begin p 11
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 785 786 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 815 816 815 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
The correlation of the clinical characteristics and the FLT3 ITD or TKD mutations at diagnosis was analyzed in 226 patients with AML, including or excluding those with M3 disease. Differences in the median variables of age, peripheral white blood cell (WBC) counts, platelet counts and the serum lactate dehydrogenase (LDH) concentration were analyzed by the Mann-Whitney U test. The analysis of data frequencies was performed using the Fisher's exact test for 2 x 2 tables or the chi-square test for larger tables. Survival probabilities were estimated by the Kaplan-Meyer method, and differences in the survival distributions were evaluated by the log-rank test. These statistical analyses were performed with SPSS software, version 13.0 (Chicago, IL, U.S.A.). For all analyses, the p values were 2-tailed, and a p value of less than 0.05 was considered statistically significant.
###end p 11
###begin title 12
RESULTS
###end title 12
###begin title 13
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of AML patients with or without FLT3 mutations
###end title 13
###begin p 14
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 291 292 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 489 496 489 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
Among the 226 AML patients, 29 (12.8%) had an ITD, 6 (2.7%) had a TKD and 191 (84.5%) had neither (wild type). No patient had an ITD and TKD concomitantly. When compared to patients with the wild type, the patients with an ITD or a TKD were significantly older (p=0.020) and had higher WBC (p=0.008) counts. Their subtypes were most frequently from M0 to M5. The presence of FLT3 mutations was not related to gender, previous hematological disease, cytogenetic changes, or high serum LDH (Table 1).
###end p 14
###begin title 15
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
The effect of FLT3 mutations on remission and survival
###end title 15
###begin p 16
###xml 428 429 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
Among the 193 patients receiving induction chemotherapy, 182 patients were available to evaluate for remission and 151 patients achieved complete remission; the remission rate (RR) was 78%. Nine patients died of therapy-related complications within 30 days. Among 22 patients with an ITD at diagnosis, 19 patients achieved remission. There was no significant difference in the RR between patients with an ITD and the wild type (p=0.651). Therefore, the presence of a FLT3 mutation did not influence the RR (p=0.824).
###end p 16
###begin p 17
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 630 636 630 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 924 931 924 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 953 957 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
At a median follow-up of 61 (11-123) months, 90 of the 236 patients (39.8%) were still alive. The median overall survival (OS) was 14 (95% CI, 12-17), 14 (4-23) and 14 (10-18) months in all patients, those with an ITD and those with the wild type, respectively (p=0.530). The median event-free survival (EFS) was 10 (8-12), 7 (2-11) and 11 (7-14) months for all patients, those with an ITD and those with the wild type, respectively (p=0.094). When excluding the M3 types (N=20), comparison of the OS between the ITD and wild type patients showed no difference; however, the EFS with an ITD was significantly shortened (p=0.0079, Fig. 1). In the multivariate analysis in treated non-M3 patients (N=176), the significant factors influencing the OS and the EFS were cytogenetic risk group (23), the presence of a complete remission after the first induction and post-remission transplantation either autologous or allogeneic (Table 2). However, neither a FLT3 mutation nor an ITD affected survival in this analysis.
###end p 17
###begin title 18
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
Variability of the FLT3 mutation
###end title 18
###begin p 19
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 46 52 46 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 324 331 <span type="species:ncbi:9606">patient</span>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
###xml 499 506 <span type="species:ncbi:9606">patient</span>
###xml 568 575 <span type="species:ncbi:9606">patient</span>
The changes of the FLT3 ITD are summarized in Fig. 2. At hematological remission, all samples were negative for an ITD even if there was an initially positive ITD (N=14). The ITD reappeared with relapse in 6 out of 9 patients, and was de novo in one of 45 patients. Induction failures with a persistent ITD were common. One patient had a lately occurred ITD at the second induction failure. The TKD changes were evaluated in patients from one center. Among 23 samples at relapse, two had a TKD. One patient had a TKD initially, and it reappeared on relapse. The other patient had an ITD only at diagnosis, and showed a newly appeared TKD at remission, which persisted at relapse and during the refractory period despite negative conversion of ITD.
###end p 19
###begin title 20
DISCUSSION
###end title 20
###begin p 21
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 700 704 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 853 857 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
Our study showed a low frequency of FLT3 ITD and TKD, 12.8% and 2.7%, respectively, in Korean AML patients. This frequency was about two-thirds lower than reports from other Asian and Western patients. (1, 2, 4, 8-13, 19, 24). A recent Korean study on M3 disease showed a relatively low frequency of ITD and TKD, 12.0% and 9.3% (25). Another unpublished Korean report also showed a low frequency of the FLT3 mutation in AML patients, the ITD was 10.4% and the TKD was 9.1% (26). To determine the association with age, we separated the patients into 148 adults and 72 pediatric patients. The adult group had the FLT3 mutation in 16% of cases and the pediatric group in 6%. Previous reports showed the FLT3 mutation in 20-30% of adults and in 9-11.5% of pediatric aged patients (27, 28). Therefore, the information to date shows that the frequency of the FLT3 mutation, especially the ITD, is low in Korean AML patients in both the adult and pediatric age groups.
###end p 21
###begin p 22
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
The prognostic value of the FLT3 mutation in AML was evaluated in a group of patients with normal karyotypes excluding those with known prognostic cytogenetic changes. About half of the AML patients had a normal karyotype or an intermediate cytogenetic risk (24, 29). The FLT3 ITD at diagnosis in these patients was associated with a significantly shortened EFS and OS (8-17). Therefore, intensified consolidation including transplantation or clinical trials targeting the FLT3 mutation should be considered in patients with an ITD (30, 31). The variability of the FLT3 ITD, during treatment in this study, supports a pattern of reappearance of the ITD with disease relapse and persistent ITD in refractory disease, which suggests chemo-resistance of the ITD-positive leukemic clones.
###end p 22
###begin p 23
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Our study included only 20 patients with M3. Recently several studies reported that M3 patients with ITD had a poor survival (25, 32). Clinical trials with FLT3-targeting agents to ATRA and anthracycline-based treatment may provide more information on the role of FLT3 in M3.
###end p 23
###begin p 24
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
Although a more sensitive method for detection of ITD, such as the genescan technique, (21) was not used in our trial, all samples at remission were negative for ITD. In a follow-up to our study (data not included) genescan detected ITD in three out of 101 samples at remission. Therefore, future studies should use the more sensitive methods now available instead of the PCR.
###end p 24
###begin p 25
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
In summary, this study included the largest number of Korean patients with AML to date, and showed a relatively low frequency of FLT3 ITD consistent with prior reports. ITD in Korean non-M3 AML patients was associated with poor EFS. In addition, the variability of ITD, during treatment follow-up, suggested chemo-resistance of the ITD-positive leukemic clones. Therefore, aggressive therapeutic approaches should be considered in AML patients with ITD at diagnosis.
###end p 25
###begin title 26
ACKNOWLEDGMENTS
###end title 26
###begin p 27
We particularly thank Hee Geun Kang, R.N. and Jung In Jue, R.N. for assistance with the data management.
###end p 27
###begin article-title 28
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
###end article-title 28
###begin article-title 29
###xml 193 201 <span type="species:ncbi:9606">patients</span>
Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodyplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
###end article-title 29
###begin article-title 30
###xml 8 13 <span type="species:ncbi:9606">human</span>
FLT3 in human hematologic malignancies
###end article-title 30
###begin article-title 31
###xml 66 71 <span type="species:ncbi:9606">human</span>
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
###end article-title 31
###begin article-title 32
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
###end article-title 32
###begin article-title 33
A new recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
###end article-title 33
###begin article-title 34
The role of FLT3 in haematopoietic malignancies
###end article-title 34
###begin article-title 35
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
###end article-title 35
###begin article-title 36
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
###end article-title 36
###begin article-title 37
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy
###end article-title 37
###begin article-title 38
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
###end article-title 38
###begin article-title 39
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)
###end article-title 39
###begin article-title 40
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
###end article-title 40
###begin article-title 41
###xml 97 105 <span type="species:ncbi:9606">patients</span>
The presence of FLT3/ITD mutations is an independent prognostic factor in acute myeloid leukemia patients with normal karyotype
###end article-title 41
###begin article-title 42
Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia
###end article-title 42
###begin article-title 43
Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia
###end article-title 43
###begin article-title 44
Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene
###end article-title 44
###begin article-title 45
Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications
###end article-title 45
###begin article-title 46
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
###end article-title 46
###begin article-title 47
Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases
###end article-title 47
###begin article-title 48
Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy
###end article-title 48
###begin article-title 49
FLT3/internal tandem duplication in paired presentation and relapse pediatric AML
###end article-title 49
###begin article-title 50
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">children</span>
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties
###end article-title 50
###begin article-title 51
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients
###end article-title 51
###begin article-title 52
Inferior prognostic outcome in acute promyelocytic leukemia with alteration of FLT3 gene
###end article-title 52
###begin article-title 53
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Analysis of FLT3-activiating mutations in 77 patients with acute myelogenous leukemia; association with WHO classification
###end article-title 53
###begin article-title 54
###xml 40 48 <span type="species:ncbi:9606">children</span>
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
###end article-title 54
###begin article-title 55
###xml 49 57 <span type="species:ncbi:9606">children</span>
FLT3 mutations determine the clinical outcome in children with de novo acute myelogenous leukemia (AML) and normal karyotype: Pediatric Oncology Group (POG) Study # 9421
###end article-title 55
###begin article-title 56
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
###end article-title 56
###begin article-title 57
NCRI Adult Leukaemia Working Party. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
###end article-title 57
###begin article-title 58
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges
###end article-title 58
###begin article-title 59
Impact of FLT3 mutations and promyelocytic leukaemiabreakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia
###end article-title 59
###begin p 60
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Event-free survival according to FLT3-ITD in 206 patients with non-M3 AML.
###end p 60
###begin p 61
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
Changes of FLT3-ITD during follow-up.
###end p 61
###begin p 62
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
ITD+, FLT3-ITD positive, and ITD-, FLT3 wild type. A (numeral)/B (numeral) means a number of patients with FLT3-ITD/tested patients.
###end p 62
###begin p 63
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient and disease characteristics according to FLT3 mutational status
###end p 63
###begin p 64
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 3 7 3 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT3</italic>
###xml 127 133 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*, FLT3 internal tandem duplication (ITD) or D835 point mutation of tyrosine kinase domain (TKD) was identified in this group; dagger, mixed means biphenotypic or bilineage leukemia.
###end p 64
###begin p 65
RAEB-t, refractory anemia with excess blast in transformation; CBC, complete blood count; LDH, latacte dehydrogenase.
###end p 65
###begin p 66
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Multivariate analysis of the significant factors for event-free (EFS) and overall survival (OS) in treated non-M3 patients (N=176)
###end p 66
###begin p 67
HR, hazard ratio; Cyto, cytogenetic 3 risk groups consisted of favorable, intermediate, and adverse risk groups; 1st CR, complete hematologic remission to the first induction treatment; SCT, stem cell transplantation.
###end p 67

